We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Smallest Microscope Views Live Tissue in Real Time

By LabMedica International staff writers
Posted on 03 Feb 2010
The world's smallest flexible microscope is diagnosing cancer and other deadly diseases, allowing physicians to treat patients on the spot. More...


Dr. Michel Kahaleh, associate professor of medicine in the division of gastroenterology and hepatology at the University of Virginia Health System (Charlottesville, USA), is utilizing the new technology, called probe-based confocal laser endomicroscopy (pCLE). pCLE is a technique that allows the user to view live tissue in real time at the cellular level. This allows the identification of cancer with pinpoint precision and permits precise removal of the diseased tissue.

"Until now, if we found suspicious tissue during one of these diagnostic procedures, we often had to randomly sample it and send it to the laboratory for analysis, which can take up to a week,” said Dr. Kahaleh. "With pCLE, we can pinpoint the dangerous tissue during the initial diagnostic procedure and remove or treat it the same day.”

Dr. Kahaleh and his team are using pCLE to effectively distinguish cancerous and precancerous tissue during colonoscopies, upper endoscopies, and the conventional pancreatic and bile duct cancer detection procedure. They are also using pCLE to find and treat gastrointestinal cancers and other gastrointestinal (GI) diseases, including those of the colon, bile duct, pancreas, and esophagus. "This new imaging tool gives us the opportunity to immediately see changes up to the cell level and potentially gain insights of what may be wrong, thus optimizing patient treatment,” Dr. Kahaleh explained.

Dr. Kahaleh also believes that this technique represents the future of medicine a future in which doctors and researchers deliver ways to diagnose and treat diseases all at once. He thinks this will save time and reduce trauma for patients while improving efficiency.

Cellvizio is the technology platform that enables the pCLE technique. It was cleared by the U.S. Food & Drug Administration (FDA) for use in the gastrointestinal tract and lungs, and over 5,000 Cellvizio procedures have been completed worldwide to date. The technology was developed by Mauna Kea Technologies (Paris, France).

Related Links:
University of Virginia Health System
Mauna Kea Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.